Digest · 25 September 2026
European hard tech, a quieter week — but a high-signal one. After September's space deluge, the deep-tech money this week swung toward sovereignty on the ground: defence, health and critical materials. Lisbon’s TEKEVER nearly quintupled its valuation to $6.4B with the first tranche of a $580M Series D for its battlefield drones; London’s Basecamp Research banked a $140M Series C from an investor list that includes Nvidia and Anthropic to turn a planet-scale biological dataset into AI-designed medicines; and UK nuclear startup StandardX launched with a £10M seed to build a sovereign isotope refinery for cancer care — and, eventually, fusion fuel. Looming over all of it is Eindhoven’s EUCLYD, whose €200M+ Series A (co-led by Samsung and EQT’s Scaleup Europe Fund, with ex-ASML chief Peter Wennink as chairman) is the largest European deep-tech round of the period — but it points hiring at a recruiting inbox rather than a public careers page, so it’s left off the linked list below, alongside London battery-diagnostics seed AcouBatt (£1.1M, UCL spin-out). Here are the rounds with a live careers link, biggest first. Figures as reported — verify on each company’s site.
Lisbon, Portugal · tekever.com · 23 Sep · defence UAS & ISR · ~$6.4B valuation
TEKEVER builds uncrewed aerial systems and the AI-driven intelligence, surveillance and reconnaissance software that runs on them — its AR-series drones already fly maritime and border-surveillance missions across Europe. The first stage of a $580M Series D roughly quintuples its valuation to about $6.4B, fresh off a £400M UK drone deal, and funds production scale-up and international expansion across its aerospace, defence and security divisions. A defence-manufacturing raise of this size points to sustained senior hiring across production and industrialisation, systems and software engineering, platform and payload engineering, quality and certification, forward-deployed field roles, plus programme delivery and government-facing commercial leadership. → Careers
London, UK (+ Cambridge, MA) · basecamp-research.com · 23 Sep · AI-designed therapeutics
Basecamp Research samples biodiversity from extreme environments worldwide and turns it into the Trillion Gene Atlas — the dataset behind EDEN, its biological foundation model for designing peptides, enzymes and cell and gene therapies. The oversubscribed $140M Series C, led by S32 with strategic backers including Nvidia and Anthropic, funds a new generation of its AI models and a push toward the clinic. Scaling a wet-lab-plus-AI drug engine points to hiring across bioinformatics and computational biology, ML and mathematical-foundations research, production sequencing and lab operations, data and platform engineering, plus partnerships and commercial leadership. → Careers
London, UK · standardx.tech · 23 Sep · accelerator-based isotope refinery
Founded by nuclear engineers Richard Pearson and Ross Allen, StandardX is building an accelerator-driven refinery that can produce a broad portfolio of rare isotopes from a single compact industrial platform — starting with the materials behind cancer diagnosis and targeted alpha therapy, and extending to tritium for fusion developers. The £10M seed, led by Vsquared Ventures and East X Ventures with firstminute capital, UKI2S, Brevan Howard Macro Venture and Geometry, funds the team, a first London industrial site and the design and build of its first refinery, with pilot production targeted for 2027. Building sovereign isotope supply points to hiring across accelerator and target engineering, nuclear and mechanical engineering, radiation safety and regulatory/licensing, control & instrumentation, ML/simulation, plus medical partnerships and commercial roles. → Careers
If September’s headline was sovereignty in orbit, this week’s was sovereignty on the ground — and in the bloodstream. The three linked rounds all point at European self-reliance in things that used to be imported: battlefield drones and ISR (TEKEVER), AI-designed medicines built on proprietary biological data (Basecamp Research), and a domestic supply of the rare isotopes hospitals and fusion developers depend on (StandardX). Around them, the “AI-meets-atoms” supply chain kept raising even when the cheques were quieter: EUCLYD’s €200M+ for low-power AI silicon and AcouBatt’s seed for listening inside battery cells during manufacturing. Nearly all of it is capital for the industrial phase — new sites, first production, qualification for volume, clinical push. The recurring HardTech Careers pattern holds: a fresh European deep-tech round is usually the signal that the binding constraint is shifting from R&D to manufacturing, regulatory approval, deployment and commercial leadership — which is exactly where the senior hiring lands.